BIOMAT Database Logo BIOMAT Database Logo

Plasma fibronectin and angiotensin-converting enzyme: markers of primary pulmonary injury in burn patients. 1994

F Plassart, and L Cynober, and B Baudin, and N Lioret, and B Bénéteau-Burnat, and X B Nolland, and R Saizy, and J Giboudeau
Laboratoire de Biochimie A., Hôpital Saint-Antoine, Paris, France.

Plasma fibronectin (FBN) and angiotensin I-converting enzyme (ACE) were prospectively measured in 50 burn patients from the day of admission to day 28 after the trauma with the aim of finding biochemical markers of pulmonary injury by smoke inhalation. Patients were divided into three groups on the basis of fiberoptic bronchoscopy results (group I: healthy lungs; group II: burned lungs; group III: infected lungs). A decrease in FBN concentrations was observed in the three groups but was larger in group II than in the other groups, especially at day 2 (P < 0.05). A similar profile was observed for plasma ACE activity. Factors other than lung injury may influence plasma FBN and ACE levels, in particular the burned body surface area, an acute event such as septicemia, or outcome. However, repeated measurements of both markers could help in the assessment of lung injury in the follow-up of burn patients.

UI MeSH Term Description Entries
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008297 Male Males
D009961 Orosomucoid Acid Seromucoid,Seromucoid,Serum Sialomucin,alpha 1-Acid Glycoprotein,alpha 1-Acid Seromucoid,A(1)-Acid Seromucoid,Acid alpha 1-Glycoprotein,Alpha(1)-Acid Glycoprotein,alpha 1-Acid Glycoprotein (Acute Phase),alpha 1-Glycoprotein Acid,Acid alpha 1 Glycoprotein,Glycoprotein, alpha 1-Acid,Seromucoid, Acid,Seromucoid, alpha 1-Acid,Sialomucin, Serum,alpha 1 Acid Glycoprotein,alpha 1 Acid Seromucoid,alpha 1 Glycoprotein Acid
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D005260 Female Females
D005353 Fibronectins Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins. Cold-Insoluble Globulins,LETS Proteins,Fibronectin,Opsonic Glycoprotein,Opsonic alpha(2)SB Glycoprotein,alpha 2-Surface Binding Glycoprotein,Cold Insoluble Globulins,Globulins, Cold-Insoluble,Glycoprotein, Opsonic,Proteins, LETS,alpha 2 Surface Binding Glycoprotein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015208 Smoke Inhalation Injury Pulmonary injury following the breathing in of toxic smoke from burning materials such as plastics, synthetics, building materials, etc. This injury is the most frequent cause of death in burn patients. Inhalation Injury, Smoke,Injury, Smoke Inhalation,Inhalation Injuries, Smoke,Injuries, Smoke Inhalation,Smoke Inhalation Injuries

Related Publications

F Plassart, and L Cynober, and B Baudin, and N Lioret, and B Bénéteau-Burnat, and X B Nolland, and R Saizy, and J Giboudeau
Angiotensin converting enzyme expression in primary pulmonary hypertension.
October 1996, American journal of respiratory and critical care medicine,
F Plassart, and L Cynober, and B Baudin, and N Lioret, and B Bénéteau-Burnat, and X B Nolland, and R Saizy, and J Giboudeau
Compared evolution of plasma fibronectin and angiotensin-converting enzyme levels in septic ARDS.
February 1985, Chest,
F Plassart, and L Cynober, and B Baudin, and N Lioret, and B Bénéteau-Burnat, and X B Nolland, and R Saizy, and J Giboudeau
[Behavior of plasma ACE (angiotensin-converting enzyme) in pulmonary silicosis].
January 1979, La Medicina del lavoro,
F Plassart, and L Cynober, and B Baudin, and N Lioret, and B Bénéteau-Burnat, and X B Nolland, and R Saizy, and J Giboudeau
Plasma fibronectin concentrations in patients with severe burn injury.
August 1984, Burns, including thermal injury,
F Plassart, and L Cynober, and B Baudin, and N Lioret, and B Bénéteau-Burnat, and X B Nolland, and R Saizy, and J Giboudeau
Angiotensin-converting enzyme and lung injury.
September 1984, The American review of respiratory disease,
F Plassart, and L Cynober, and B Baudin, and N Lioret, and B Bénéteau-Burnat, and X B Nolland, and R Saizy, and J Giboudeau
Angiotensin-converting enzyme and pulmonary sarcoidosis.
June 1981, Comprehensive therapy,
F Plassart, and L Cynober, and B Baudin, and N Lioret, and B Bénéteau-Burnat, and X B Nolland, and R Saizy, and J Giboudeau
Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension.
November 2000, The Journal of pathology,
F Plassart, and L Cynober, and B Baudin, and N Lioret, and B Bénéteau-Burnat, and X B Nolland, and R Saizy, and J Giboudeau
Angiotensin-converting enzyme from porcine plasma.
June 1971, Biochimica et biophysica acta,
F Plassart, and L Cynober, and B Baudin, and N Lioret, and B Bénéteau-Burnat, and X B Nolland, and R Saizy, and J Giboudeau
Pulmonary angiotensin-converting enzyme antienzyme antibody.
November 1976, Biochemistry,
F Plassart, and L Cynober, and B Baudin, and N Lioret, and B Bénéteau-Burnat, and X B Nolland, and R Saizy, and J Giboudeau
Plasma angiotensin-converting enzyme in Alzheimer's disease.
January 2009, Journal of Alzheimer's disease : JAD,
Copied contents to your clipboard!